SCHEMBL24257775

SCHEMBL24257775

CCOC(=O)CNC(=O)c1ncc(C#CSI)c(C)c1OO

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.37
RAB9A P51151 3/20 0.37
ALDH1A1 P00352 7/20 0.36
HPGD P15428 4/20 0.36
HSD17B10 Q99714 2/20 0.36
LMNA P02545 2/20 0.36
SMN1; SMN2 Q16637 4/20 0.36
MAPT P10636 1/20 0.35
EGLN1 Q9GZT9 3/20 0.34
POLB P06746 1/20 0.34
VEGFA P15692 1/20 0.33
FLT1 P17948 1/20 0.33
EGLN3 Q9H6Z9 1/20 0.33
KDM4E B2RXH2 1/20 0.33
CASP1 P29466 1/20 0.33
CASP7 P55210 1/20 0.33
GAA P10253 2/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24257625 0.84 ALDH1A1 (0.39) NPC1RAB9AALDH1A1HPGDHSD17B10
SCHEMBL26260156 0.76 SMN1; SMN2 (0.37) NPC1RAB9AALDH1A1HPGDHSD17B10
SCHEMBL26260159 0.74 SMN1; SMN2 (0.39) NPC1RAB9AALDH1A1HPGDHSD17B10
SCHEMBL26260138 0.72 SMN1; SMN2 (0.43) NPC1RAB9AALDH1A1HPGDHSD17B10
SCHEMBL24257782 0.72 EGLN1 (0.42) NPC1ALDH1A1HPGDHSD17B10LMNA
SCHEMBL24257741 0.71 SMN1; SMN2 (0.39) NPC1RAB9AALDH1A1HPGDHSD17B10
SCHEMBL24257706 0.70 ALDH1A1 (0.43) NPC1RAB9AALDH1A1HPGDHSD17B10
SCHEMBL26260136 0.70 SMN1; SMN2 (0.45) NPC1RAB9AALDH1A1HPGDHSD17B10
SCHEMBL24257632 0.69 EGLN1 (0.56) NPC1RAB9AALDH1A1HPGDLMNA
SCHEMBL26263986 0.69 EGLN1 (0.44) NPC1RAB9AALDH1A1HPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
WO-2022036188-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE HIF1AN, EGLN3, PHF20 NPC1 4011/4885RAB9A 739/4885ALDH1A1 1362/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.